CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next ...

Professor Richard Scolyer, marked his 250th Parkrun. He battles an aggressive brain cancer. Scolyer underwent experimental immunotherapy. Doctors confirmed a recurrence. He turned his illness into a ...

Posters will be available in the publications section of Compugen’s website, www.cgen.com, following presentation.

Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow ...